DDInter1826 DDInter264
A sulphonylurea hypoglycemic agent with actions and uses similar to those of chlorpropamide.
Asparaginase is an important agent used to treat acute lymphoblastic leukemia (ALL) . Asparagine is incorporated into most proteins, and the synthesis of proteins is stopped when asparagine is absent, which inhibits RNA and DNA synthesis, resulting in a halt in cellular proliferation. This forms the basis of asparaginase treatment in ALL , , . Calaspargase pegol, also known as _asparlas_, is an asparagine specific enzyme which is indicated as a part of a multi-agent chemotherapy regimen for the treatment of ALL . The asparagine specific enzyme is derived from Escherichia coli, as a conjugate of L-asparaginase (L-asparagine amidohydrolase) and monomethoxypolyethylene glycol (mPEG) with a succinimidyl carbonate (SC) linker to create a stable molecule which increases the half-life and decreases the dosing frequency [FDA label], . Calaspargase pegol, by _Shire_ pharmaceuticals, was approved by the FDA on December 20, 2018 for acute lymphoblastic anemia (ALL) .
Tolazamide {u} (Compound) resembles {v} (Compound) Glipizide
Glipizide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Calaspargase pegol
Tolazamide {u} (Compound) resembles {v} (Compound) Glipizide
Glipizide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Liraglutide
Liraglutide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Calaspargase pegol
Tolazamide {u} (Compound) resembles {v} (Compound) Sulfacetamide
Sulfacetamide {u} (Compound) resembles {v} (Compound) Tolbutamide
Tolbutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Calaspargase pegol
Tolazamide {u} (Compound) resembles {v} (Compound) Tolbutamide
Tolbutamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Clopidogrel
Clopidogrel {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Calaspargase pegol
Tolazamide {u} (Compound) resembles {v} (Compound) Glipizide
Glipizide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nateglinide
Nateglinide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Calaspargase pegol
Tolazamide {u} (Compound) resembles {v} (Compound) Gliclazide
Gliclazide {u} (Compound) resembles {v} (Compound) Glimepiride
Glimepiride {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Calaspargase pegol
Tolazamide {u} (Compound) treats {v} (Disease) type 2 diabetes mellitus
type 2 diabetes mellitus {u} (Disease) is treated by {v} (Compound) Pioglitazone
Pioglitazone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Calaspargase pegol
Tolazamide {u} (Compound) binds {v} (Gene) KCNJ1
KCNJ1 {u} (Gene) is bound by {v} (Compound) Glimepiride
Glimepiride {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Calaspargase pegol
Tolazamide {u} (Compound) upregulates {v} (Gene) TSC22D3
TSC22D3 {u} (Gene) is upregulated by {v} (Compound) Sorafenib
Sorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Calaspargase pegol
Tolazamide {u} (Compound) is included by {v} (Pharmacologic Class) Sulfonylurea Compounds
Sulfonylurea Compounds {u} (Pharmacologic Class) includes {v} (Compound) Glimepiride
Glimepiride {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Calaspargase pegol
Tolazamide (Compound) resembles Glipizide (Compound) and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Tolazamide (Compound) resembles Glipizide (Compound) and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide and Liraglutide may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Tolazamide (Compound) resembles Sulfacetamide (Compound) and Sulfacetamide (Compound) resembles Tolbutamide (Compound) and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Tolazamide (Compound) resembles Tolbutamide (Compound) and Tolbutamide may cause a minor interaction that can limit clinical effects when taken with Clopidogrel and Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Tolazamide (Compound) resembles Glipizide (Compound) and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Tolazamide (Compound) resembles Gliclazide (Compound) and Gliclazide (Compound) resembles Glimepiride (Compound) and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Tolazamide (Compound) treats type 2 diabetes mellitus (Disease) and type 2 diabetes mellitus (Disease) is treated by Pioglitazone (Compound) and Pioglitazone may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Tolazamide (Compound) binds KCNJ1 (Gene) and KCNJ1 (Gene) is bound by Glimepiride (Compound) and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Tolazamide (Compound) upregulates TSC22D3 (Gene) and TSC22D3 (Gene) is upregulated by Sorafenib (Compound) and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Tolazamide (Compound) is included by Sulfonylurea Compounds (Pharmacologic Class) and Sulfonylurea Compounds (Pharmacologic Class) includes Glimepiride (Compound) and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol